, Volume 7, Issue 4, pp 335–337 | Cite as

Targeting glia for treatment of neurological disease

  • David A. Rempe
  • Maiken Nedergaard


  1. 1.
    Nagai M, Re DB, Nagata T, et al. Astrocytes expressing ALS-linked mutated SOD1 release factors selectively toxic to motor neurons. Nat Neurosci 2007;10: 615–622.CrossRefPubMedGoogle Scholar
  2. 2.
    Zhao BQ, Wang S, Kim HY, et al. Role of matrix metalloproteinases in delayed cortical responses after stroke. Nat Med 2006;12: 441–445.CrossRefPubMedGoogle Scholar
  3. 3.
    Ehrenreich H, Weissenborn K, Range H, et al. Recombinant human erythropoietin in the treatment of acute ischemic stroke. Stroke 2009;40: e647-e656.CrossRefPubMedGoogle Scholar
  4. 4.
    Asano T, Mori T, Shimoda T, et al. Arundic acid (ONO-2506) ameliorates delayed ischemic brain damage by preventing astrocytic overproduction of S100B. Curr Drug Targets CNS Neurol Disord 2005;4: 127–142.CrossRefPubMedGoogle Scholar

Copyright information

© Springer 2010

Authors and Affiliations

  • David A. Rempe
    • 1
  • Maiken Nedergaard
    • 2
  1. 1.Department of Neurology, Stroke Division Center for Neural Development and DiseaseUniversity of Rochester School of Medicine and DentistryRochester
  2. 2.Division of Glia Disease and Therapeutic Center for Translational Neuromedicine Department of NeurosurgeryUniversity of Rochester School of Medicine and DentistryRochester

Personalised recommendations